Amarin Corp. ADR buy Cantor Fitzgerald
Start price
21.12.23
/
50%
€0.77
Target price
21.12.24
-
Performance (%)
11.69%
Price
30.04.24
€0.86
Summary
This prediction is currently active. The prediction currently has a performance of 11.69%. This prediction currently runs until 21.12.24. The prediction end date can be changed by Cantor_Fitzgerald at any time. Cantor_Fitzgerald has 50% into this predictionAmarin Corporation plc (Symbol AMRN) is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to improve cardiovascular health. The company's main product, Vascepa, is a prescription medication that has been approved by the US FDA for use as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. Vascepa has also shown to reduce the risk of cardiovascular events such as heart attack and stroke in patients with elevated cardiovascular risk. As a listed company, Amarin is publicly traded on the NASDAQ stock exchange and has a market capitalization of approximately $5 billion as of August 2021.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Amarin Corp. ADR | 4.242% | 4.242% |
| iShares Core DAX® | -1.370% | -3.231% |
| iShares Nasdaq 100 | 0.172% | -3.339% |
| iShares Nikkei 225® | -0.801% | -7.859% |
| iShares S&P 500 | -0.369% | -2.979% |
Comments by Cantor_Fitzgerald for this prediction
In the thread Amarin Corp. ADR diskutieren
Amarin Co. plc (NASDAQ: AMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for AMRN provided by MarketBeat